Natera president Solomon Moshkevich sells $1.24m in shares

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), sold shares of the company’s common stock totaling $1,242,645 on October 1, 2026.

The transactions involved multiple sales of shares, executed under a Rule 10b5-1 trading plan adopted by Moshkevich on November 26, 2024. These sales included 200 shares at a weighted average price of $411.62 per share, 954 shares at a weighted average price of $413.1066 per share, and 1,846 shares at a weighted average price of $415.0691 per share. The prices for these transactions ranged between $411.62 and $415.0691 per share.The sale comes as Natera trades near its 52-week high of $427.47, following a remarkable 145% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among the most overvalued stocks in the market.

Following these reported transactions, Moshkevich directly holds 106,914 shares of Natera common stock.For investors seeking deeper insights into Natera’s valuation and growth prospects, InvestingPro offers 16 additional ProTips and comprehensive Pro Research Reports covering over 1,400 US equities.

In other recent news, Natera reported second-quarter revenue of approximately $753 million, surpassing Wall Street’s expectations of $661.26 million. This revenue growth was attributed to accelerated performance across its primary business areas. Natera’s management also raised the full-year revenue guidance, highlighting record test volumes, improved margins, and several regulatory achievements. Additionally, RBC Capital increased its price target for Natera to $460, maintaining an Outperform rating, based on the company’s promising growth prospects in minimal residual disease (MRD) testing. Rothschild Redburn initiated coverage of Natera with a Buy rating and set a price target of $385, recognizing the company’s leadership in MRD testing with its Signatera and Latitude tests. These developments reflect Natera’s strong position in a market with significant potential.